<table cellpadding="0.4pt" cellspacing="0pt" id="_RefSPLSERV-5F803C84-0814-7E4E-CD29-39FE" width="80%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3:  Clinically Significant Drug Interactions with ADDYI</caption>
<col width="28%"></col>
<col width="63%"></col>
<tbody>
<tr>
<td colspan="2" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Alcohol</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Clinical Implications </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> The concomitant use of ADDYI with alcohol increased the risk of hypotension, syncope, and CNS depression compared to the use of ADDYI alone or alcohol alone <content stylecode="italics">[see <linkhtml href="#ID_10681d53-47cb-ed6d-e9bf-508b12567310">Warnings and Precautions (5.1)</linkhtml> and <linkhtml href="#ID_d2d49ddf-3c09-3463-7f88-465c04cecf06">Clinical Pharmacology (12.2)</linkhtml>].</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Preventing or Managing DI </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> The concomitant use of ADDYI with alcohol is contraindicated<content stylecode="italics">.</content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Other CNS Depressants </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Examples </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Diphenhydramine, opioids, hypnotics, benzodiazepines  </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Clinical Implications </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> The concomitant use of ADDYI with CNS depressants may increase the risk of CNS depression (e.g., somnolence) compared to the use of ADDYI alone. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Preventing or Managing DI </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Discuss the concomitant use of other CNS depressants with the patient when prescribing ADDYI. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Moderate or Strong CYP3A4 Inhibitors</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Examples of strong CYP3A4 inhibitors </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Examples of moderate CYP3A4 inhibitors </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Amprenavir, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, verapamil, and grapefruit juice </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Clinical Implications </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> The concomitant use of ADDYI with moderate or strong CYP3A4 inhibitors increases flibanserin exposure compared to the use of ADDYI alone. The risk of hypotension and syncope is increased with concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors <content stylecode="italics">[see <linkhtml href="#ID_5fcfa933-9c39-8497-9571-db827b297ee1">Warnings and Precautions (5.3)</linkhtml>, <linkhtml href="#ID_7cd92052-fcc1-d86a-f017-54c613249254">Adverse Reactions (6.1)</linkhtml>, and <linkhtml href="#ID_02f47d1f-f6d7-de9b-71ba-afe1287842a5">Clinical Pharmacology (12.3)</linkhtml>].</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Preventing or Managing DI </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> The concomitant use of ADDYI with moderate or strong CYP3A4 inhibitors is contraindicated<content stylecode="italics">. </content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Weak CYP3A4 Inhibitors</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Examples  </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Clinical Implications </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Preventing or Managing DI </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Discuss the use of multiple weak CYP3A4 inhibitors with the patient when prescribing ADDYI. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Strong CYP2C19 Inhibitors</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Examples </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, antifungals </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Clinical Implications </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> The concomitant use of ADDYI with strong CYP2C19 inhibitors may increase flibanserin exposure which may increase the risk of hypotension, syncope, and CNS depression. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Preventing or Managing DI </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Discuss the use of a strong CYP2C19 inhibitor with the patient when prescribing ADDYI. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">CYP3A4 Inducers</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Examples </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapetine, St. John's Wort </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Clinical Implications </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> The concomitant use of ADDYI with CYP3A4 inducers substantially decreases flibanserin exposure compared to the use of ADDYI alone. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Preventing or Managing DI </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> The concomitant use of ADDYI with CYP3A4 inducers is not recommended. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Digoxin or Other P-glycoprotein Substrates</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Examples </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Digoxin, sirolimus </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> Clinical Implications </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph> The concomitant use of ADDYI with digoxin, a drug that is transported by P-glycoprotein (P-gp), increases the digoxin concentration <content stylecode="italics">[see <linkhtml href="#ID_02f47d1f-f6d7-de9b-71ba-afe1287842a5">Clinical Pharmacology (12.3)</linkhtml>]</content>.  This may lead to digoxin toxicity. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph> Preventing or Managing DI </paragraph>
</td>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph> Increase monitoring of concentrations of drugs transported by P-gp that have a narrow therapeutic index (e.g., digoxin).   </paragraph>
</td>
</tr>
</tbody>
</table>